AR021106A1 - COMBINED THERAPY OF AN ANGIOTENSIN CONVERTER ENZYME INHIBITOR AND AN ALDOSTERONE ANTAGONIST TO REDUCE MORBILITY AND MORTALITY BY CARDIOVASCULAR DISEASES - Google Patents

COMBINED THERAPY OF AN ANGIOTENSIN CONVERTER ENZYME INHIBITOR AND AN ALDOSTERONE ANTAGONIST TO REDUCE MORBILITY AND MORTALITY BY CARDIOVASCULAR DISEASES

Info

Publication number
AR021106A1
AR021106A1 ARP990105623A AR021106A1 AR 021106 A1 AR021106 A1 AR 021106A1 AR P990105623 A ARP990105623 A AR P990105623A AR 021106 A1 AR021106 A1 AR 021106A1
Authority
AR
Argentina
Prior art keywords
reduce
morbility
mortality
cardiovascular diseases
enzyme inhibitor
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of AR021106A1 publication Critical patent/AR021106A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen combinaciones de un inhibidor ACE y un antagonista del receptor de aldosterona para su uso en el tratamiento de trastornos circulatorios. Sonde particular interés las terapias con captopril, enalapril o lisinopril co-administradas con espironolactona. Esta coterapia será de particular utilidad parareducir el índice de mortalidad o la cantidad de internaciones no fatales o para prevenir el avance de la insuficiencia cardíaca congestiva en pacientes conenfermedades cardiovasculares.Combinations of an ACE inhibitor and an aldosterone receptor antagonist are described for use in the treatment of circulatory disorders. Of particular interest are therapies with captopril, enalapril or lisinopril co-administered with spironolactone. This therapy will be particularly useful to reduce the death rate or the number of non-fatal hospitalizations or to prevent the progression of congestive heart failure in patients with cardiovascular disease.

ARP990105623 1998-11-06 1999-11-05 COMBINED THERAPY OF AN ANGIOTENSIN CONVERTER ENZYME INHIBITOR AND AN ALDOSTERONE ANTAGONIST TO REDUCE MORBILITY AND MORTALITY BY CARDIOVASCULAR DISEASES AR021106A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10739898P 1998-11-06 1998-11-06

Publications (1)

Publication Number Publication Date
AR021106A1 true AR021106A1 (en) 2002-06-12

Family

ID=22316456

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105623 AR021106A1 (en) 1998-11-06 1999-11-05 COMBINED THERAPY OF AN ANGIOTENSIN CONVERTER ENZYME INHIBITOR AND AN ALDOSTERONE ANTAGONIST TO REDUCE MORBILITY AND MORTALITY BY CARDIOVASCULAR DISEASES

Country Status (3)

Country Link
AR (1) AR021106A1 (en)
TW (1) TWI238716B (en)
ZA (1) ZA200103632B (en)

Also Published As

Publication number Publication date
ZA200103632B (en) 2002-05-06
TWI238716B (en) 2005-09-01

Similar Documents

Publication Publication Date Title
EA200100418A1 (en) COMBINED THERAPY WITH THE USE OF ANGIOTENZIN CONVERSION AND ANTAGONIST ALDOSTERONE ENVIRONMENTAL INHIBITOR TO REDUCE INCIDENCE AND MORTALITY IN CARDIOVASCULAR DISEASES
FR16C0028I2 (en) VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS
TW200616632A (en) Compounds modulating c-kit activity and uses therefor
RS20150135A1 (en) Treatment with anti-vegf antibodies
SG155188A1 (en) Pyrrole derivatives as pharmaceutical agents
WO2005001080A3 (en) Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
WO2006050058A3 (en) Methods of detection and therapy of inflamed tissues using immune modulation
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
NO20060027L (en) Antibodies to connective tissue growth factor
SG149027A1 (en) Substituted urea derivatives for treating cardiac diseases
ATE433973T1 (en) AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES
TW200509910A (en) Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
WO2004032852A3 (en) Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
NO20073651L (en) Antiangiogenesis therapy of autoimmune disease in patients with failed previous therapy
CO5660287A2 (en) DERIVATIVES OF TETRAHYDROCARBAZOL AND ITS PHARMACEUTICAL USE
SG156681A1 (en) Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
MX2007013834A (en) Vascular disease therapies.
PL1853270T3 (en) Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
EA200400399A1 (en) METHODS OF TREATMENT OF PULMONARY DISEASES
EA200100951A1 (en) COMBINED THERAPY WITH INHIBITOR ANGIOTENZIN-CONVERTING ENZYME AND EPOXYSTROID ANTAGONIST ALDOSTERONE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
EA201070195A1 (en) DERIVATIVES 1,2,3,4-TETRAGIDROPYRROLO [1,2-A] PIRAZIN-6-CARBOXAMIDES AND 2,3,4,5-TETRAHYDROPYRROLO [1,2-a] [1,4] -DIAZEPIN-7-CARBOXAMIDES , THEIR RECEIVING AND THEIR APPLICATION IN THERAPY
BR9604882A (en) Combination therapy of anti-biotin conversion enzyme inhibitor and amount of reduced side effect of aldosterone antagonist for the treatment of cardiovascular disease
AR021106A1 (en) COMBINED THERAPY OF AN ANGIOTENSIN CONVERTER ENZYME INHIBITOR AND AN ALDOSTERONE ANTAGONIST TO REDUCE MORBILITY AND MORTALITY BY CARDIOVASCULAR DISEASES
NO993399L (en) Use of angiotensin II antagonists to treat symptomatic heart failure
DK1478362T3 (en) Combination therapy for acute myocardial infarction

Legal Events

Date Code Title Description
FB Suspension of granting procedure